DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ipratropium (Ipratropium Bromide Monohydrate Inhalation) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Ipratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution, 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis.

DOSAGE AND ADMINISTRATION

The recommended dose of ipratropium bromide nasal solution, 0.03% is two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day) for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Optimum dosage varies with the response of the individual patient.

Initial pump priming requires seven sprays of the pump. If used regularly as recommended, no further priming is required. If not used for more than 24 hours, the pump will require two sprays, or if not used for more than seven days, the pump will require seven sprays to reprime. Avoid spraying into eyes.

HOW SUPPLIED

Ipratropium bromide nasal solution, 0.03% is supplied in a white high density polyethylene (HDPE) bottle fitted with a metered nasal spray pump, a green safety clip to prevent accidental discharge of the spray, and a clear plastic dust cap (NDC 60505-0826-1). It contains 31.1g of product formulation, 345 sprays, each delivering 21 mcg (70 mcL) of ipratropium bromide per spray, or 28 days of therapy at the maximum recommended dose (two sprays per nostril three times a day).

Store tightly closed at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature]. Avoid freezing. Keep out of reach of children. Do not spray in the eyes.

Avoid freezing. Keep out of reach of children. Do not spray in the eyes.

Patients should be reminded to read and follow the accompanying “Patient’s Instructions for Use”, which should be dispensed with the product.

Manufactured by:                            Manufactured for:

Apotex Inc.                                    Apotex Corp.

Toronto, Ontario                             Weston, FL

Canada M9L 1T9                            33326

273885

October 2008

 

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012